Lilly rose about 2.9% at the beginning of the session, hitting a high of $866.5. According to the news, Eli Lilly's Q4 revenue was US$13.53 billion, up 45% year over year, while analysts' expectations were US$13.57 billion; adjusted earnings per share were US$5.32, higher than analysts' expectations of US$4.95. Mounjaro's revenue increased 60% year over year to $3.53 billion during the period. Eli Lilly says it plans to release late-stage clinical trial data for its next-generation weight loss drug Retatrutide later this year, several months ahead of expectations.

Lilly rose about 2.9% at the beginning of the session, hitting a high of $866.5. According to the news, Eli Lilly's Q4 revenue was US$13.53 billion, up 45% year over year, while analysts' expectations were US$13.57 billion; adjusted earnings per share were US$5.32, higher than analysts' expectations of US$4.95. Mounjaro's revenue increased 60% year over year to $3.53 billion during the period. Eli Lilly says it plans to release late-stage clinical trial data for its next-generation weight loss drug Retatrutide later this year, several months ahead of expectations.